Interrupted Etanercept Therapy: A New Case Report  

作　　者：Waqas S. Abdulwahhab Alaa S. Mehair Waqas S. Abdulwahhab;Alaa S. Mehair(Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, United Arab Emirates;College of Medicine, University of Sharjah, Sharjah, United Arab Emirates)

机构地区：[1]Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, United Arab Emirates [2]College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

出　　处：《Journal of Cosmetics, Dermatological Sciences and Applications》2021年第2期71-75,共5页化妆品、皮肤病及应用期刊（英文）

摘　　要：Psoriasis is a chronic, immune-mediated, inflammatory disease with a high prevalence in the general population (2%). The anti-tumor necrosis factor receptor etanercept is Food and Drug Administration (FDA) approved for the treatment of moderate-to-severe plaque psoriasis. Both continuous and interrupted etanercept therapy is effective and well-tolerated. This report <strong>aims</strong> to document a new case presentation of psoriasis on intermittent etanercept injection throughout 36 weeks with long-lasting sustained efficacy and no risk factor. <strong>Case Report</strong>: A 39-year-old adult male patient with long-standing chronic plaque psoriasis for 15 years duration without joint involvement started loading dose treatment of etanercept injection in whom due to his work circumstances not taken maintenance therapy and showed-up at the clinic after 36 weeks from first induction therapy when partial relapse of psoriatic lesions appear in last week with continued improvement when reintroducing loading treatment on followed-up over the next 36 weeks. <strong>Conclusion</strong>: Intermittent etanercept therapy considers effective for 36 weeks with prolonging sustained efficacy and without adverse effect.Psoriasis is a chronic, immune-mediated, inflammatory disease with a high prevalence in the general population (2%). The anti-tumor necrosis factor receptor etanercept is Food and Drug Administration (FDA) approved for the treatment of moderate-to-severe plaque psoriasis. Both continuous and interrupted etanercept therapy is effective and well-tolerated. This report <strong>aims</strong> to document a new case presentation of psoriasis on intermittent etanercept injection throughout 36 weeks with long-lasting sustained efficacy and no risk factor. <strong>Case Report</strong>: A 39-year-old adult male patient with long-standing chronic plaque psoriasis for 15 years duration without joint involvement started loading dose treatment of etanercept injection in whom due to his work circumstances not taken maintenance therapy and showed-up at the clinic after 36 weeks from first induction therapy when partial relapse of psoriatic lesions appear in last week with continued improvement when reintroducing loading treatment on followed-up over the next 36 weeks. <strong>Conclusion</strong>: Intermittent etanercept therapy considers effective for 36 weeks with prolonging sustained efficacy and without adverse effect.

关 键 词：ADHERENCE Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) ETANERCEPT Interrupted Therapy PSORIASIS 

分 类 号：R75[医药卫生—皮肤病学与性病学]